PCM
AGIO icon

Piermont Capital Management’s Agios Pharmaceuticals AGIO Stock Holding History

Piermont Capital Management’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-18,980
Closed -$977K – 245
2017
Q2 		$977K Sell
18,980
-440
-2% -$22.5K 0.28% 143
2017
Q1 		$1.13M Buy
19,420
+7,820
+67% +$375K 0.27% 143
2016
Q4 		$484K Sell
11,600
-230
-2% -$12.1K 0.11% 226
2016
Q3 		$625K Buy
+11,830
New +$515K 0.15% 216

Other funds holding AGIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Piermont Capital Management's AGIO Position: Q3 2017 in Review

Piermont Capital Management sold out of Agios Pharmaceuticals (AGIO) in Q3 2017, closing a stake of 18,980 shares — an estimated $977K sold.

Piermont Capital Management first reported a position in AGIO in Q3 2016 and held it in 4 quarters. The position peaked at $1.13M in Q1 2017. 171 funds tracked by Wall St. Rank hold AGIO as of Q3 2017.

  • Piermont Capital Management reported no remaining Agios Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
  • Piermont Capital Management sold 18,980 Agios Pharmaceuticals shares in Q3 2017, an estimated $977K.
  • Piermont Capital Management first reported a position in Agios Pharmaceuticals in Q3 2016 and held it in 4 quarters.
  • Piermont Capital Management's Agios Pharmaceuticals position peaked at $1.13M in Q1 2017.
  • 171 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q3 2017.

Based on Piermont Capital Management's 13F filing for Q3 2017, filed 14 Nov 2017.